Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.

The Journal of clinical investigation - 15 Jun 2022

Aykul Senem, Huang Lily, Wang Lili, Das Nanditha M, Reisman Sandra, Ray Yonaton, Zhang Qian, Rothman Nyanza, Nannuru Kalyan C, Kamat Vishal, Brydges Susannah, Troncone Luca, Johnsen Laura, Yu Paul B, Fazio Sergio, Lees-Shepard John, Schutz Kevin, Murphy Andrew J, Economides Aris N, Idone Vincent, Hatsell Sarah J

Abstract excerpt

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder whose most debilitating pathology is progressive and cumulative heterotopic ossification (HO) of skeletal muscles, ligaments, tendons, and fascia. FOP is caused by mutations in the type I BMP receptor gene ACVR1, which enable ACVR1 to utilize its natural antagonist, activin A, as an agonistic ligand. The physiological relevance of this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activin Receptors, Type I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies

Share to Ligands

Share to Mutation

Share to Myositis Ossificans

Share to Ossification, Heterotopic

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 35511419
DOI: 10.1172/JCI153792
PMCID: PMC9197526

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.PMID 35511419Read ↗

An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro/adipogenic progenitors in fibrodysplasia ossificans progressiva miceSemantic proximity Read ↗

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice.Semantic proximity Read ↗

Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology.Semantic proximity Read ↗

The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.Semantic proximity Read ↗

The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-DependentSemantic proximity Read ↗

Over-expression of wild-type <i>ACVR1</i> in fibrodysplasia ossificans progressiva mice rescues perinatal lethality and inhibits heterotopic ossificationSemantic proximity Read ↗

iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

Fibrodysplasia ossificans progressiva emerges from obscurity.Semantic proximity Read ↗

Fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.Semantic proximity Read ↗

Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.